Auspex
Pharmaceuticals Inc. (Nasdaq: ASPX) reported positive results from a Phase 3
clinical trial of SD-809 for treating chorea associated with
Huntington's disease sending the stock price soaring $25.05 to close at $50.14.
Auspex Pharmaceuticals reports positive trial data
December 17, 2014 at 16:38 PM EST